Kindstar Globalgene Technology, Inc. (HK:9960) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kindstar Globalgene Technology, Inc. has voluntarily announced its acquisition of approximately 11.38% equity interest in Beijing Bofurui Gene Diagnostic Technology Co., Ltd., a leader in transplantation esoteric testing and professional services in China. The acquisition, valued at RMB31,876,000, is part of Kindstar’s strategy to enhance its esoteric testing capabilities and market influence in transplantation services. The deal does not make the target company a subsidiary, nor will it be reflected in Kindstar’s consolidated financial statements.
For further insights into HK:9960 stock, check out TipRanks’ Stock Analysis page.

